PL2475645T3 - 5-(3,4-dichlorofenylo)-n-(2-hydroksycykloheksylo)-6-(2,2,2- trifluoroetoksy)nikotynoamid i jego sole jako środki zwiększające poziom cholesterolu hdl - Google Patents

5-(3,4-dichlorofenylo)-n-(2-hydroksycykloheksylo)-6-(2,2,2- trifluoroetoksy)nikotynoamid i jego sole jako środki zwiększające poziom cholesterolu hdl

Info

Publication number
PL2475645T3
PL2475645T3 PL10749873T PL10749873T PL2475645T3 PL 2475645 T3 PL2475645 T3 PL 2475645T3 PL 10749873 T PL10749873 T PL 10749873T PL 10749873 T PL10749873 T PL 10749873T PL 2475645 T3 PL2475645 T3 PL 2475645T3
Authority
PL
Poland
Prior art keywords
nicotinamide
trifluoro
dichloro
ethoxy
cyclohexyl
Prior art date
Application number
PL10749873T
Other languages
English (en)
Inventor
Stephan Roever
Matthew Wright
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2475645T3 publication Critical patent/PL2475645T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL10749873T 2009-09-11 2010-09-08 5-(3,4-dichlorofenylo)-n-(2-hydroksycykloheksylo)-6-(2,2,2- trifluoroetoksy)nikotynoamid i jego sole jako środki zwiększające poziom cholesterolu hdl PL2475645T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11
EP10749873.5A EP2475645B1 (en) 2009-09-11 2010-09-08 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents
PCT/EP2010/063136 WO2011029827A1 (en) 2009-09-11 2010-09-08 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents

Publications (1)

Publication Number Publication Date
PL2475645T3 true PL2475645T3 (pl) 2013-12-31

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10749873T PL2475645T3 (pl) 2009-09-11 2010-09-08 5-(3,4-dichlorofenylo)-n-(2-hydroksycykloheksylo)-6-(2,2,2- trifluoroetoksy)nikotynoamid i jego sole jako środki zwiększające poziom cholesterolu hdl

Country Status (35)

Country Link
US (1) US8227491B2 (pl)
EP (1) EP2475645B1 (pl)
JP (1) JP5604520B2 (pl)
KR (1) KR101382871B1 (pl)
CN (1) CN102639506B (pl)
AR (2) AR078352A1 (pl)
AU (1) AU2010294277B2 (pl)
BR (1) BR112012005511B8 (pl)
CA (1) CA2771493C (pl)
CL (1) CL2012000611A1 (pl)
CO (1) CO6491033A2 (pl)
CR (1) CR20120089A (pl)
CY (1) CY1114377T1 (pl)
DK (1) DK2475645T3 (pl)
EC (1) ECSP12011723A (pl)
ES (1) ES2423821T3 (pl)
HK (1) HK1172021A1 (pl)
HR (1) HRP20130869T1 (pl)
IL (1) IL217920A (pl)
IN (1) IN2012DN00763A (pl)
MA (1) MA33563B1 (pl)
MX (1) MX2012002254A (pl)
MY (1) MY161103A (pl)
NZ (1) NZ597514A (pl)
PE (1) PE20120863A1 (pl)
PL (1) PL2475645T3 (pl)
PT (1) PT2475645E (pl)
RS (1) RS52987B (pl)
RU (1) RU2541475C2 (pl)
SG (1) SG179035A1 (pl)
SI (1) SI2475645T1 (pl)
TW (1) TWI412363B (pl)
UA (1) UA107088C2 (pl)
WO (1) WO2011029827A1 (pl)
ZA (1) ZA201201599B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
CA2602787C (en) * 2005-04-06 2013-12-24 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
CA2664119A1 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents

Also Published As

Publication number Publication date
ECSP12011723A (es) 2012-04-30
EP2475645A1 (en) 2012-07-18
BR112012005511B1 (pt) 2021-03-02
AR078352A1 (es) 2011-11-02
UA107088C2 (xx) 2014-11-25
CY1114377T1 (el) 2016-08-31
RU2541475C2 (ru) 2015-02-20
CR20120089A (es) 2012-03-22
HK1172021A1 (en) 2013-04-12
IL217920A (en) 2015-11-30
KR101382871B1 (ko) 2014-04-08
RU2012113924A (ru) 2013-10-20
PT2475645E (pt) 2013-08-05
HRP20130869T1 (hr) 2013-10-25
WO2011029827A1 (en) 2011-03-17
RS52987B (en) 2014-02-28
CA2771493A1 (en) 2011-03-17
CA2771493C (en) 2017-08-29
MX2012002254A (es) 2012-03-16
AU2010294277B2 (en) 2015-07-09
SI2475645T1 (sl) 2013-10-30
TWI412363B (zh) 2013-10-21
DK2475645T3 (da) 2013-07-22
BR112012005511B8 (pt) 2021-05-25
MA33563B1 (fr) 2012-09-01
TW201114427A (en) 2011-05-01
ZA201201599B (en) 2012-11-28
US20110065759A1 (en) 2011-03-17
CN102639506A (zh) 2012-08-15
CN102639506B (zh) 2014-09-03
BR112012005511A2 (pt) 2016-04-19
AR114032A2 (es) 2020-07-15
US8227491B2 (en) 2012-07-24
IL217920A0 (en) 2012-03-29
IN2012DN00763A (pl) 2015-06-26
JP2013504534A (ja) 2013-02-07
NZ597514A (en) 2013-10-25
CO6491033A2 (es) 2012-07-31
ES2423821T3 (es) 2013-09-24
AU2010294277A1 (en) 2012-02-09
JP5604520B2 (ja) 2014-10-08
CL2012000611A1 (es) 2012-09-07
EP2475645B1 (en) 2013-07-03
SG179035A1 (en) 2012-04-27
KR20120048040A (ko) 2012-05-14
PE20120863A1 (es) 2012-07-23
MY161103A (en) 2017-04-14

Similar Documents

Publication Publication Date Title
HK1172021A1 (en) 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro- ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents hdl 5-(34--)-n-(2--)-6-(222-- )-
EP2360155A4 (en) 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
HK1135983A1 (en) Multi-substituted pyridyl sulfoximines and their use as insecticides
IL197577A0 (en) 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents
HK1183018A1 (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use 4-(4--2-)
IL204663A0 (en) Nicotinamide derivatives, preparastion thereof and therapeutic use thereof
EP1876178A4 (en) CYANOPYRIDINE DERIVATIVE AND THE USE THEREOF AS A MEDICAMENT
ZA200808191B (en) Pyridine and pyrimidine derivatives as MGLUR2 antagonists
IL217774A0 (en) Compositions for treating gaucher disease and uses thereof
PT2493306E (pt) Composição herbicida sinergistica coontendo fluroxipir e cihalofop
IL220571A (en) Compounds of 3 - (3-phenyl-imidazo [5,4- b] pyridinyl) -2-conjugated aminopyridine and pharmaceutical preparations containing them
HK1150555A1 (zh) 用於治療動脈硬化的 -嘧啶二元胺的應用
RS52256B2 (sr) Terapeutske upotrebe jedinjenja sa kombinovanim sert, 5-ht3 i 5-ht1a aktivnostima
BRPI1015967A2 (pt) "unidade de dobradiça, e, peça de mobília."
IL210937A (en) New phenyl – amino isonicotinamide compounds and their use
HRP20171742T1 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
SG10201402634SA (en) Muteins of the pyrroline-5-carboxylate reductase 1
EP2276501A4 (en) METHODS AND COMPOSITIONS AGAINST GENETIC AND NETWORK DISEASES
HK1172835A1 (en) Fluoro-substituted 3,5-dicyano-4-(1h-indazol-5-yl)2,6-dimethyl-1,4- dihydropyridine derivatives and methods of use thereof 35--4-(1h--5-)-26--14-
IL197013A0 (en) Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
EP2497768A4 (en) NEW 2,4-PYRIMIDINE DERIVATIVES AND USES THEREOF
EP2190990A4 (en) PTHRP, its isoforms and antagonist for the diagnosis and treatment of diseases